Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 10;12(11):3322. doi: 10.3390/cancers12113322

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The steady state concentrations of gefitinib (A), erlotinib (B), and afatinib (C) in different blood compartments. Samples for gefitinib (whole blood and plasma) were obtained after an average of 124 ± 67 days at 250 mg per dose level. Samples for erlotinib were obtained after an average of 238 ± 167 days at 150 mg per dose level. Samples for afatinib were obtained after 4 days following standard 40 mg oral dosing per day. Values are the means ± standard error of the mean of 4 or more replicates as indicated in the text.